Valion Bio (VBIO) Non-Current Assets (2021 - 2026)

Valion Bio has reported Non-Current Assets for 6 years, with the latest figure at $29.1 million in Q2 2026.

• On a quarterly basis, Non-Current Assets rose 991.19% year-over-year to $29.1 million in Q2 2026; TTM through Jun 2026 was $52.8 million, a 846.91% increase from a year earlier, with the FY2025 full-year figure at $18.6 million, up 10972.02% from the prior year.
• Non-Current Assets was $29.1 million for Q2 2026 at Valion Bio, up from $18.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $29.1 million in Q2 2026, with the low at $120000.0 in Q2 2024.
• Average Non-Current Assets over 5 years is $3.6 million, with a median of $614000.0 recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 79.87% in 2024, then surged 10972.02% in 2025.
• Over 5 years, Non-Current Assets stood at $569000.0 in 2022, then slipped by 11.25% to $505000.0 in 2023, then sank by 66.73% to $168000.0 in 2024, then soared by 10972.02% to $18.6 million in 2025, then soared by 56.39% to $29.1 million in 2026.
• The last three Non-Current Assets figures came in at $29.1 million (Q2 2026), $18.6 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.